###begin article-title 0
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
SnoN is an important regulator of the transforming growth factor beta (TGFbeta) signalling pathway and has been shown to exhibit both tumour promotion and suppression activity.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
To further explore the role of this complex molecule in colorectal tumorigenesis, we examined 52 paired normal and tumour colorectal specimens stratified by level of microsatellite instability; 18 with high-level microsatellite instability (MSI-H) and 34 microsatellite stable (MSS). SnoN transcript expression was quantitated by real-time PCR and analysed with respect to clinical indicators of prognosis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 442 453 440 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 489 494 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
Within the MSI-H subgroup, SnoN was commonly either up-regulated (6/18, 33%) or down-regulated (7/18, 39%). A significantly different distribution of SnoN expression was observed in MSS cancers compared with MSI-H (P </= 0.001). Whilst 17/34 (50%) of MSS tumours demonstrated up-regulation, none showed down-regulated expression. Within the MSI-H subgroup, up-regulation was significantly correlated with lack of repeat tract mutation in the TGFbetaRII gene (P </= 0.025), suggesting that SnoN is more frequently up-regulated in the presence of functional TGFbeta signalling.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Together these data support the notion that SnoN has both oncogenic and tumour suppressive properties depending on other genetic changes within the tumour, and that the MSI-H pathway of colorectal tumorigenesis presents an excellent model for the study of these opposing functions.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 6 9 6 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ski</italic>
###xml 10 28 10 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">related novel gene</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ski </italic>
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 219 220 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 221 222 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 462 463 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 464 465 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 466 467 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 468 469 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 573 578 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 592 593 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 615 617 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 558 563 <span type="species:ncbi:10090">mouse</span>
###xml 602 607 <span type="species:ncbi:9606">human</span>
###xml 713 718 <span type="species:ncbi:9606">human</span>
SnoN (ski-related novel gene) is a member of the highly homologous Ski gene family [1], and can act as a repressor of the TGF-beta signalling pathway through either SnoN homodimerisation or heterodimerisation with Ski [1-6]. This repression is mediated through binding of SnoN to SMAD proteins, which are responsible for the propagation of signals initiated by TGF-beta ligand for the transcription of genes required for cell growth control and differentiation [1,4,7,8]. Conversely, SnoN has also been shown to suppress tumour growth both in a heterozygote mouse model of SnoN inactivation [9] and in human cells [10]. These opposing functions have led to difficulty in interpreting the complex roles of SnoN in human malignancies.
###end p 11
###begin p 12
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ski </italic>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ski </italic>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN</italic>
###xml 744 749 741 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 501 508 <span type="species:ncbi:9606">patient</span>
Both SnoN and Ski have been implicated in the development of human cancers including colon [11], breast [12], melanoma [3] and oesophageal cancers [13]. Expression of SnoN has not previously been examined in colorectal cancer (CRC), although a study of gene copy number status showed that the SnoN locus was partially or completely deleted in 55% of CRCs and amplified in 15% [11]. Interestingly, increased copy number of Ski was found to be a negative prognostic indicator whilst no correlation with patient outcome was observed for SnoN. Since regulation of TGFbeta signalling by SnoN involves a combination of proteolytic degradation and transcriptional up-regulation in addition to changes in copy number, we suggest that quantification of SnoN expression may be a more informative way to assess its role in colorectal tumour development.
###end p 12
###begin p 13
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Colorectal tumours stratified by level of microsatellite instability represent two principal pathways of sporadic colorectal tumorigenesis. The majority of sporadic CRCs are microsatellite stable (MSS) and aneuploid. These have been well studied but are understood to be heterogeneous at the molecular level [14]. Cancers displaying a high level of microsatellite instability (MSI-H) comprise approximately 15% of all sporadic CRCs, are diploid and generally have a favourable prognosis [15]. Whilst the major mechanisms for gene inactivation in MSS cancers are mutation and deletion, MSI-H tumours progress predominantly due to repeat-tract mutation and aberrant promoter hypermethylation of important target tumour suppressor genes [16].
###end p 13
###begin p 14
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
We have examined the frequency of altered SnoN expression in a series of CRCs stratified by MSI-status. Based on our findings we propose that MSI-H cancers present an excellent model for studying the dual roles of SnoN in both tumour suppression and promotion.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient specimens
###end title 16
###begin p 17
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT25</italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAT26</italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D5S346</italic>
###xml 473 480 473 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D2S123 </italic>
###xml 484 491 484 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D17S250</italic>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 154 159 <span type="species:ncbi:9606">Women</span>
###xml 198 203 <span type="species:ncbi:9606">Human</span>
###xml 305 310 <span type="species:ncbi:9606">Women</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">Patients</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
###xml 800 807 <span type="species:ncbi:9606">patient</span>
###xml 877 885 <span type="species:ncbi:9606">Patients</span>
Fifty-two paired normal and tumour tissue specimens were obtained in a fresh state from colectomy specimens surgically resected at the Royal Brisbane and Women's Hospital between 1993 and 2005. The Human Research Ethics Committee of the Queensland Institute of Medical Research and the Royal Brisbane and Women's Hospital Research Ethics Committee approved this study and all patients provided written informed consent. The standard panel of markers (BAT25, BAT26, D5S346, D2S123 and D17S250) recommended by a National Cancer Institute workshop were used to determine the MSI-status of the cancers, as previously described [17]. Patients were classified as microsatellite instability high (MSI-H) if >30% of markers showed instability. The remainder of patients were microsatellite stable (MSS). The patient cohort was enriched for MSI-H tumours, but was otherwise unselected. Patients with familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC) were excluded from the study.
###end p 17
###begin title 18
Expression analysis
###end title 18
###begin p 19
###xml 1450 1452 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1554 1559 1482 1487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 2049 2051 1977 1979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2052 2054 1980 1982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1295 1302 <span type="species:ncbi:9606">patient</span>
Total RNA was extracted from tissue samples which had been snap frozen in liquid nitrogen then stored at -80degreesC using the QIAGEN RNeasy Midi Kit. Total RNA (5 mug) was reverse transcribed using random hexamers and SuperScript III Reverse Transcriptase (Invitrogen, USA). Semi-quantitative real-time polymerase chain reaction was performed using a Corbett Rotor-Gene 3000 machine (Corbett Research, Australia) with the following gene specific primers: Reference gene, beta-ActinF: 5'-TCATGAAGTGTGACGTGGACATC-3'; beta-ActinR: 5'-CAGGAGGAGCAATGATCTTGATCT-3'; Gene Of Interest, SnoNF: 5'-CACCCCAGCTACTACTTATAC-3', SnoNR: 5'-TTGCCTCTGTCTTTGTGAGC-3') and Platinum SYBR Green qPCR Supermix-UDG (Invitrogen, USA). Each reaction contained 8 muL of qPCR mix, 5 pmol of each forward and reverse primer and 4 muL of diluted cDNA template. The following cycling conditions were applied: 50degreesC for 2 min, 95degreesC for 2 min, followed by 45 cycles of 95degreesC for 15 sec, 59degreesC for 15 sec, 72degreesC for 20 sec, 76degreesC of 15 sec. Data for each cycle was acquired after the final cycling step. A melt ramp consisting of 1degreesC increments from 60degreesC to 99degreesC (30 sec first step, 1 sec for subsequent steps) followed the 45 cycles. Each reaction was carried out in duplicate (patient samples) or triplicate (calibrator). The relative expression of SnoN to beta-Actin was calculated using the method previously described by Pfaffl [18]. qPCR results from each set of reaction replicates varied no more than 5% from the mean. Normalised SnoN expression values (R) for all tumours were divided by the R value for their matched normal mucosa to indicate fold up-regulation, the inverse gave a whole number to indicate fold down-regulation. Data was analysed based on empirical fold differences (student's T-test) as well as number of tumours showing greater than 2 fold up- or down-regulation (Pearson's chi square). The cut-off of 2-fold was arbitrarily chosen as significant, based on previous reports in the colorectal literature [19,20].
###end p 19
###begin title 20
TGFbetaRII mutation analysis
###end title 20
###begin p 21
###xml 48 51 48 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 64 108 64 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">transforming growth factor &#946; receptor II </italic>
###xml 109 119 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII</italic>
###xml 411 412 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The presence of somatic mutations in the poly(A)10 tract of the transforming growth factor beta receptor II (TGFbetaRII) coding sequence was investigated in MSI-H tumours by PCR followed by direct manual sequencing of the adenosine nucleotide. Both 1-bp and 2-bp deletions are predicted to result in a truncated protein product. The PCR consisted of a 50 muL reaction containing 250 ng template DNA, 1.5 mM MgCl2, 0.2 mM nucleotides, 20 pmol forward and reverse primers, 1X Gold Buffer and 2U AmpliTaq Gold (Applied Biosystems). Primers were TGFBR2f: 5'-CTTTATTCTGGAAGATGCTGC-3' and TGFBR2r: 5'-GATGATGTTGTCATTGCACTC-3'. Following column purification (QIAGEN) 1 muL of PCR product was subjected to direct manual sequencing using the same forward and reverse primers with the Ampli-Cycle cycle sequencing kit (Perkin Elmer). The 115-bp product was electrophoresed on a 6% denaturing polyacrylamide gel for 75 minutes.
###end p 21
###begin title 22
Clinical correlates
###end title 22
###begin p 23
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">Patients</span>
###xml 339 346 <span type="species:ncbi:9606">patient</span>
Disease-staging data was obtained for all patients according to the ACPS [21] and TNM staging systems [22]. TNM staging provided information on the extent of primary tumour invasion (T), local lymph node spread (N) and metastasis to a distant site (M). Patients were followed for an average of 43 months and clinical data was recorded for patient age, sex and tumour anatomical location. Tumour recurrence, death due to cancer and death due to any other cause were also noted.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Tabular data were analysed by Pearson's chi square using Web Chi Square Calculator [23] to determine significance. Non-parametric t-tests (Mann-Whitney) were performed using GraphPad Prism version 4.00 for Windows [24]. P-values less than 0.05 were considered statistically significant.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
SnoN expression levels compared with MSI-status
###end title 27
###begin p 28
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 504 509 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 714 719 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Transcript levels of SnoN were examined in 34 MSS and 18 MSI-H tumours relative to matched normal mucosa. There was a significantly different distribution of expression observed in MSI-H compared to MSS cancers (P < 0.01). Whilst expression varied from 9.2 fold down-regulated to 38.1 fold up-regulated in MSI-H cancers, the majority of MSS cancers showed expression higher than matched normal mucosa levels, to a maximum of 10.5 fold (Fig. 1). Considering >2 fold expression differences as significant, SnoN was up-regulated in 6/18 (33%) MSI-H cancers, whilst expression was down-regulated in 7/18 (39%) tumours in this group. By contrast, within the MSS tumour group, cancers were equally likely to demonstrate SnoN up-regulation (17/34, 50%) as they were to show no change in expression level (17/34, 50%) (Table 1, P < 0.001). Significance was maintained even when the cut-off was reduced to 1.5 fold de-regulation (P < 0.001).
###end p 28
###begin title 29
SnoN expression levels compared with clinical features
###end title 29
###begin p 30
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 875 880 875 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 77 84 <span type="species:ncbi:9606">patient</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
No significant correlations were observed between SnoN expression levels and patient age, sex, site or ACPS stage (Table 1). Evaluation of extent of tumour invasion (T), local spread to lymph nodes (N) or distant metastatic spread (M) derived from the TNM staging system did not reveal any significant correlations. Within the MSS group, more patients without increased SnoN expression had a stage D tumour, as compared with those patients with increased SnoN expression (Table 1). Of patients with a stage A, B or C tumour, 3 had a recurrence of cancer. None of these tumours showed increased SnoN expression. When these two groups were combined to indicate a poor prognosis, there was a statistically significant association between poor outcome and failure to elevate SnoN (Table 1, P < 0.025). There were only two stage D MSI-H tumours, neither of which showed increased SnoN expression.
###end p 30
###begin title 31
TGFbetaRII mutation
###end title 31
###begin p 32
###xml 90 101 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 113 114 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 228 233 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 336 341 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 391 402 388 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
Fifteen MSI-H tumours were assessed for repeat tract mutation in the coding region of the TGFbetaRII gene (Table 2). Mutations were detected in 12/15 (80%). Interestingly, three out of the six tumours demonstrating up-regulated SnoN expression were wild-type for this usually common mutation, whilst all nine tumours which did not have SnoN up-regulated had a mutation of either one or both TGFbetaRII alleles (P </= 0.025).
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 148 149 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 150 152 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 267 268 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 269 271 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 307 312 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 252 258 <span type="species:ncbi:10090">murine</span>
SnoN is an important negative regulator of TGFbeta induced tumour suppression, and exerts an oncogenic effect by binding to SMAD protein complexes [7,25]. Importantly, SnoN has also been shown to suppress tumour growth in both epithelial cell line and murine models [9,10]. To further delineate the role of SnoN gene regulation in colorectal tumours, we quantified mRNA expression in a series of sporadic CRCs stratified by MSI-status.
###end p 34
###begin p 35
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 325 330 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 612 617 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 732 737 728 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
Down-regulation of a gene in a significant number of tumours compared with matched normal mucosa would usually suggest abrogation of tumour suppressor gene function. Strikingly, SnoN was down-regulated in 39% of MSI-H CRCs in this study (7/18), but not in any of the 34 MSS cancers examined (P </= 0.001). This suggests that SnoN may be an important tumour suppressor gene, exclusively in CRCs progressing via the MSI pathway of tumorigenesis. Even when the arbitrary cut-off for significant expression differences was reduced to only 1.5 fold, the statistically significant association between up-regulation of SnoN in MSS CRCs and down-regulation in MSI-H CRCs was maintained (P </= 0.001), suggesting that even subtle changes in SnoN gene expression levels are capable of exerting a functional effect.
###end p 35
###begin p 36
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 671 672 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
There is currently no evidence that the SnoN locus is a direct target for down-regulation. Although repeat-tract mutation and promoter hypermethylation are the major mechanisms of gene disruption in MSI-H CRCs, the SnoN transcript does not contain an extended repeat tract, nor does the 5' region represent a typical CpG island likely to be silenced by methylation. Whilst chromosomal instability is a characteristic feature of most MSS cancers, locus deletion is an uncommon mechanism for gene down-regulation in MSI-H tumours. It is more likely that SnoN is transcriptionally down-regulated due to disruption of the negative feedback loop involving TGFbeta signalling [7].
###end p 36
###begin p 37
###xml 174 175 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 176 178 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 267 269 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 287 289 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 322 333 313 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 389 391 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 481 486 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 514 517 499 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 542 553 527 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 589 591 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 608 613 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 775 780 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
Accumulating evidence suggests that SnoN is an important regulator of TGFbeta signalling, and acts predominantly through binding to TGFbeta signal-transducing SMAD proteins [7,25]. High levels of SnoN have been shown to inhibit TGFbeta signal transduction in breast [12] and skin cells [26]. In MSI-H tumours, mutation of TGFbetaRII causes resistance to TGFbeta-induced growth inhibition [27]. We proposed that such a situation would decrease the selection pressure to up-regulate SnoN and therefore examined the A10 repeat tract mutation of TGFbetaRII commonly observed in MSI-H cancers [28]. We found that SnoN was indeed up-regulated more commonly in tumours with a wild-type receptor sequence (P </= 0.025), which may support a link between intact TGFbeta signalling and SnoN up-regulation.
###end p 37
###begin p 38
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 859 864 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
SnoN was also up-regulated compared to matched normal mucosa in a large number of MSS cancers (17/34, 50%), however reduced expression was not observed for any MSS tumour. This is discordant with the observed frequencies of gene amplification (15%) and deletion (55%) reported by Buess and colleagues [11], and highlights the importance of examining expression levels where post-transcriptional processing may further modulate transcript levels beyond the linear affect of altered copy number. Chromosomal instability is common in MSS cancers, and usually manifests as high rates of deletion of chromosomal regions where a mutated tumour suppressor gene is located on the remaining allele. It is possible that the high rate of deletion observed by Buess and colleagues is a result of another gene target on chromosome 3q26, whilst expression of the remaining SnoN allele is increased through compensatory transcriptional mechanisms, despite hemizygous deletion.
###end p 38
###begin p 39
###xml 161 162 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 507 512 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 705 710 690 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 783 785 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 971 975 956 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN</italic>
Luo (2004) suggested that the seemingly opposing tumour promoting and suppressing roles of SnoN may reflect the likewise dual roles of TGFbeta in tumorigenesis [1]. It was proposed that early in tumour development TGFbeta signalling would be activated to facilitate growth suppression. However, subsequent disruption of TGFbeta signalling later in tumorigenesis could enhance the ability of TGFbeta to promote tumour invasion and metastasis. Therefore, abrogation of TGFbeta signalling via up-regulation of SnoN could result in tumours which are large but less likely to metastasise. This is entirely consistent with our finding of a more positive prognostic outcome in relation to cancers with increased SnoN expression. MSI is a well-established marker for a favourable prognosis [29]. This is consistent with only 2/18 of the MSI-H tumours in this series being ACPS stage D. Furthermore, it is interesting to note that neither of these cancers showed up-regulation of SnoN.
###end p 39
###begin p 40
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 71 78 <span type="species:ncbi:9606">patient</span>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
Our suggested association between failure to up-regulate SnoN and poor patient outcome in MSS cancers may be related to the role of SnoN in TGFbeta signalling. This interesting observation warrants further investigation in a larger patient cohort which would allow correction for tumour stage. Comprehensive studies are now necessary to fully elucidate the connection between disrupted TGFbeta signalling and the role SnoN may play in maintaining the balance between cell proliferation and differentiation.
###end p 40
###begin title 41
Conclusion
###end title 41
###begin p 42
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
SnoN transcript expression was commonly up-regulated in colorectal tumours, regardless of microsatellite instability status. Importantly, SnoN was also frequently down-regulated specifically in microsatellite instability high (MSI-H) colon cancers. Based on this finding, we propose that MSI-H tumours present a unique model for examining the dual suppressive and oncogenic roles of this important regulatory gene in colorectal tumorigenesis.
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
The author(s) declare that they have no competing interests.
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
###xml 130 141 130 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
JC carried out the quantitative real-time PCR assays and analysis and contributed to drafting of the manuscript. LS performed the TGFbetaRII mutation analysis. SC contributed to the real-time PCR assays and analysis. MW assisted with cohort selection and clinical analysis. JY contributed to study design and review of the manuscript. JJ contributed to study design and interpretation of results in the context of TGFbeta signalling. KS participated in study design and review of the manuscript. BL contributed to study conception and design and collected all clinical data. VW contributed to study conception, data analysis and drafting of the manuscript. All authors read and approved the final manuscript.
###end p 46
###begin title 47
Pre-publication history
###end title 47
###begin p 48
The pre-publication history for this paper can be accessed here:
###end p 48
###begin p 49

###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
This work was supported by the National Health and Medical Research Council, Queensland Cancer Fund, Queensland Health Pathology Services and the Walter Paulson Tumour Bank.
###end p 51
###begin article-title 52
Ski and SnoN: negative regulators of TGF-b signalling.
###end article-title 52
###begin article-title 53
Complex formation between proteins encoded by the ski gene family.
###end article-title 53
###begin article-title 54
###xml 62 67 <span type="species:ncbi:9606">human</span>
Repression of TGF-b signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis.
###end article-title 54
###begin article-title 55
Ski/Sno and TGF-b signalling.
###end article-title 55
###begin article-title 56
A carboxyl-terminal region of the Ski oncoprotein mediates homodimerization as well as heterodimerization with the related protein SnoN.
###end article-title 56
###begin article-title 57
A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAFII110.
###end article-title 57
###begin article-title 58
Negative feedback regulation of TGF-b signaling by the SnoN oncoprotein.
###end article-title 58
###begin article-title 59
TGF-b signaling in tumour suppression and cancer progression.
###end article-title 59
###begin article-title 60
###xml 106 110 <span type="species:ncbi:10090">mice</span>
The Sno gene, which encodes a component of the histone deactylase complex, acts as a tumour suppressor in mice.
###end article-title 60
###begin article-title 61
SnoN is a cell type-specific mediator of transforming growth factor-beta responses.
###end article-title 61
###begin article-title 62
Amplification of SKI is a prognostic marker in early colorectal cancer.
###end article-title 62
###begin article-title 63
Ski-related novel protein N (SnoN), a negative controller of Transforming Growth Factor-b signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas.
###end article-title 63
###begin article-title 64
Increased expression of c-Ski as a co-repressor in transforming growth factor-b signaling correlates with progression of esophageal squamous cell carcinoma.
###end article-title 64
###begin article-title 65
Mutations in APC, Kirsten-ras and p53 - alternative genetic pathways to colorectal cancer.
###end article-title 65
###begin article-title 66
Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
###end article-title 66
###begin article-title 67
Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers.
###end article-title 67
###begin article-title 68
A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer.
###end article-title 68
###begin article-title 69
A new mathematical model for relative quantification in real-time RT-PCR.
###end article-title 69
###begin article-title 70
Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference.
###end article-title 70
###begin article-title 71
Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptase-polymerase chain reaction.
###end article-title 71
###begin article-title 72
The prognostic value of substaging colorectal carcinoma.
###end article-title 72
###begin article-title 73
Clinical staging and end results classification: TNM system of clinical classification as applicable to carcinoma of the colon and rectum.
###end article-title 73
###begin article-title 74
Web Chi Square Calculator [http://www.georgetown.edu/faculty/ballc/webtools/web_chi.html]
###end article-title 74
###begin article-title 75
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego California USA [www.graphpad.com].
###end article-title 75
###begin article-title 76
The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins.
###end article-title 76
###begin article-title 77
Cytostatic and apoptotic actins of TGF-beta in homeostasis and cancer.
###end article-title 77
###begin article-title 78
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer.
###end article-title 78
###begin article-title 79
###xml 118 123 <span type="species:ncbi:9606">human</span>
Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers.
###end article-title 79
###begin article-title 80
Prognositc significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer.
###end article-title 80
###begin title 81
Figures and Tables
###end title 81
###begin p 82
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
Distribution of SnoN expression in tumours stratified by MSI-status. SnoN data points were determined by semi-quantitative real-time PCR and are expressed as either fold up- or down-regulated, as compared to matched normal mucosa. Whilst there was a wide range of increased and decreased expression changes in the MSI-H subgroup, no MSS tumours demonstrated down-regulation greater than 2 fold.
###end p 82
###begin p 83
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
SnoN expression differences relative to MSI-Status and Clinical Characteristics
###end p 83
###begin p 84
###xml 0 5 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</sup>
###xml 5 10 1 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
DeltaSnoN expression relative to MSI-status
###end p 84
###begin p 85
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8226; </sup>
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
* SnoN expression relative to recurrence in ACPS stage A, B or C in MSS subgroup
###end p 85
###begin p 86
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#9670; </sup>
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
â—† SnoN expression relative to the number of patients with an ACPS stage D MSS cancer, or ACPS stage A, B or C MSS cancer which recurred
###end p 86
###begin p 87
###xml 39 44 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SnoN </italic>
TGFbetaRII mutation status relative to SnoN expression
###end p 87

